These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20153617)

  • 1. Abdominal subcutaneous adipose tissue morphology in a patient with a dominant-negative mutation (P467L) in the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARG) gene.
    Boiani R; Cinti S; Savage DB; Vidal-Puig A; O'Rahilly S
    Nutr Metab Cardiovasc Dis; 2010 Mar; 20(3):e11-2. PubMed ID: 20153617
    [No Abstract]   [Full Text] [Related]  

  • 2. Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction.
    Pendse AA; Johnson LA; Tsai YS; Maeda N
    Diabetes; 2010 Nov; 59(11):2890-7. PubMed ID: 20724579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dried natto diet on the transcript levels of the peroxisome proliferator-activated receptor-γ, coactivator-1α and -1β, and nuclear receptor corepressor 1 genes in laying hens.
    Seo Y; Kubota T; Sudo M; Toda N; Ogawa Y; Miyaguchi Y
    Anim Sci J; 2021; 92(1):e13522. PubMed ID: 33624372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism.
    De Silva TM; Ketsawatsomkron P; Pelham C; Sigmund CD; Faraci FM
    Hypertension; 2015 Feb; 65(2):345-51. PubMed ID: 25385762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with peroxisome proliferator-activated receptor-γ in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction.
    Borges GR; Morgan DA; Ketsawatsomkron P; Mickle AD; Thompson AP; Cassell MD; Mohapatra DP; Rahmouni K; Sigmund CD
    Hypertension; 2014 Sep; 64(3):590-6. PubMed ID: 24914194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
    Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
    Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma/Pro12Ala polymorphism and peroxisome proliferator-activated receptor gamma coactivator-1 alpha/Gly482Ser polymorphism in patients with sarcoidosis.
    Maver A; Medica I; Salobir B; Tercelj-Zorman M; Sabovic M; Petrovic D; Peterlin B
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Sep; 25(1):29-35. PubMed ID: 19070258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG1A and PPARG are differently expressed in the liver of fat and lean broilers.
    Larkina TA; Sazanova AL; Fomichev KA; Barkova OY; Malewski T; Jaszczak K; Sazanov AA
    J Appl Genet; 2011 May; 52(2):225-8. PubMed ID: 21161624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
    Li G; Leff T
    Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
    Savage DB; Tan GD; Acerini CL; Jebb SA; Agostini M; Gurnell M; Williams RL; Umpleby AM; Thomas EL; Bell JD; Dixon AK; Dunne F; Boiani R; Cinti S; Vidal-Puig A; Karpe F; Chatterjee VK; O'Rahilly S
    Diabetes; 2003 Apr; 52(4):910-7. PubMed ID: 12663460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broiler chicken adipose tissue dynamics during the first two weeks post-hatch.
    Bai S; Wang G; Zhang W; Zhang S; Rice BB; Cline MA; Gilbert ER
    Comp Biochem Physiol A Mol Integr Physiol; 2015 Nov; 189():115-23. PubMed ID: 26263851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
    Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
    J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction.
    Ruiz-Narváez EA; Kraft P; Campos H
    Am J Clin Nutr; 2007 Oct; 86(4):1238-42. PubMed ID: 17921408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.
    Risérus U; Tan GD; Fielding BA; Neville MJ; Currie J; Savage DB; Chatterjee VK; Frayn KN; O'Rahilly S; Karpe F
    Diabetes; 2005 May; 54(5):1379-84. PubMed ID: 15855323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis.
    Marangoni RG; Korman BD; Allanore Y; Dieude P; Armstrong LL; Rzhetskaya M; Hinchcliff M; Carns M; Podlusky S; Shah SJ; Ruiz B; Hachulla E; Tiev K; Cracowski JL; Varga J; Hayes MG
    Arthritis Res Ther; 2015 May; 17(1):128. PubMed ID: 25986483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-130a regulates differential lipid accumulation between intramuscular and subcutaneous adipose tissues of pigs via suppressing PPARG expression.
    Wei W; Sun W; Han H; Chu W; Zhang L; Chen J
    Gene; 2017 Dec; 636():23-29. PubMed ID: 28882569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects.
    Kim KS; Choi SM; Shin SU; Yang HS; Yoon Y
    Metabolism; 2004 Dec; 53(12):1538-43. PubMed ID: 15562396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.